CD39/CD73 dysregulation and adenosine metabolism contribute to T cell immunosuppression in patients with Sézary syndrome

Letter to Blood| January 5, 2023 CD39/CD73 dysregulation and adenosine metabolism contribute to T-cell immunosuppression in patients with Sézary syndrome Yuliya Yakymiv, Yuliya Yakymiv ∗ 1Laboratory of Immunogenetics, Department of Medical Sciences, University of Turin, Turin, Italy https://orcid.org/0000-0002-9598-3462 Search for other works by this author on: This Site PubMed Google Scholar Sara Marchisio, Sara Marchisio ∗ 1Laboratory of Immunogenetics, Department of Medical Sciences, University of Turin, Turin, Italy https://orcid.org/0000-0001-7005-837X Search for other works by this author on: This Site PubMed Google Scholar Erika Ortolan, Erika Ortolan 1Laboratory of Immunogenetics, Department of Medical Sciences, University of Turin, Turin, Italy https://orcid.org/0000-0003-2287-9020 Search for other works by this author on: This Site PubMed Google Scholar Cristiano Bracci, Cristiano Bracci 1Laboratory of Immunogenetics, Department of Medical Sciences, University of Turin, Turin, Italy Search for other works by this author on: This Site PubMed Google Scholar Rebecca Senetta, Rebecca Senetta 2Pathology Unit, Department of Oncology, University of Turin, Turin, Italy Search for other works by this author on: This Site PubMed Google Scholar Maria Rebecca Rumore, Maria Rebecca Rumore 2Pathology Unit, Department of Oncology, University of Turin, Turin, Italy Search for other works by this author on: This Site PubMed Google Scholar Cristian Tampieri, Cristian Tampieri 3Pathology Unit, Department of Medical Sciences, University of Turin, Turin, Italy Search for other works by this author on: This Site PubMed Google Scholar Marianna Fia, Marianna Fia 4Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy Search for other works by this author on: This Site PubMed Google Scholar Simone Ribero, Simone Ribero 4Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy Search for other works by this author on: This Site PubMed Google Scholar Ada Funaro, Ada Funaro † 1Laboratory of Immunogenetics, Department of Medical Sciences, University of Turin, Turin, Italy https://orcid.org/0000-0001-6341-1817 Search for other works by this author on: This Site PubMed Google Scholar Pietro Quaglino Pietro Quaglino † 4Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy Search for other works by this author on: This Site PubMed Google Scholar Blood (2023) 141 (1): 111–116. https://doi.org/10.1182/blood.2022017259 Article history Submitted: May 31, 2022 Accepted: August 14, 2022 Connected Content This is a related article to: CD39-CD73-adenosine effects in Sézary syndrome Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Request Permissions Cite Icon Cite Search Site Citation Yuliya Yakymiv, Sara Marchisio, Erika Ortolan, Cristiano Bracci, Rebecca Senetta, Maria Rebecca Rumore, Cristian Tampieri, Marianna Fia, Simone Ribero, Ada Funaro, Pietro Quaglino; CD39/CD73 dysregulation and adenosine metabolism contribute to T-cell immunosuppression in patients with Sézary syndrome. Blood 2023; 141 (1): 111–116. doi: https://doi.org/10.1182/blood.2022017259 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsBlood Search Subjects: Immunobiology and Immunotherapy, Lymphoid Neoplasia TO THE EDITOR: Sézary syndrome (SS) is an aggressive subtype of cutaneous T-cell lymphoma, clinically presenting with erythroderma, lymphadenopathy, and atypical T cells (Sézary cells) in the skin, lymph nodes, and peripheral blood.1,2 As disease progresses, patients with SS develop severe immunodeficiency orchestrated by tumor cells and the tumor microenvironment (TME). This immunodeficiency is worsened by therapy and is responsible for a high incidence of life-threatening infections.3 Overexpression of CD39 and/or CD73 in malignant circulating SS T cells has previously been reported.4,5 Here we follow up on our preliminary data by investigating the functional role of the CD39/CD73 ectoenzymes in generating immunosuppressive extracellular adenosine (ADO) in patients with SS.6,7 Our patient cohort consisted of 11 patients with SS (supplemental Table 1, available on the Blood website). At first encounter and at... References 1.Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703-1714.Google ScholarCrossrefSearch ADS PubMed 2.Scarisbrick JJ, Hodak E, Bagot M, et al. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. Eur J Cancer. 2018;93:47-56.Google ScholarCrossrefSearch ADS PubMed 3.Quaglino P, Fava P, Pileri A, et al. Phenotypical markers, molecular mutations, and immune microenvironment as targets for new treatments in patients with mycosis fungoides and/or Sézary syndrome. J Invest Dermatol. 2021;141(3):484-495.Google ScholarCrossrefSearch ADS 4.Sonigo G, Bozonnat A, Dumont M, et al. Involvement of the CD39/CD73/adenosine pathway on T cell proliferation and NK cell-mediated ADCC in Sézary syndrome. Blood. 2022;139(17):2712-2716.Google ScholarCrossrefSearch ADS PubMed 5.Bensussan A, Janela B, Thonnart N, et al. Identification of CD39 as a marker for the circulating malignant T-cell clone of Sézary syndrome patients. J Invest Dermatol. 2019;139(3):725-728.Google ScholarCrossrefSearch ADS 6.Quaglino P, Funaro A, Ortolan E, et al. Prec-O1-05 - Flow-cytometry and functional evaluation of the CD39/CD73 adenosinergic immunosuppressive axis in patients with Sézary syndrome. Eur J Cancer. 2021;156(suppl 1):S12-S13.Google Scholar 7.Allard B, Allard D, Buisseret L, Stagg J. The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol. 2020;17(10):611-629.Google ScholarCrossrefSearch ADS PubMed 8.Bernengo MG, Novelli M, Quaglino P, et al. The relevance of the CD4+ CD26– subset in the identification of circulating Sézary cells. Br J Dermatol. 2001;144(1):125-135.Google ScholarCrossrefSearch ADS PubMed 9.Lewis DJ, Rook AH. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy. Expert Rev Anticancer Ther. 2020;20(6):447-452.Google ScholarCrossrefSearch ADS PubMed 10.Picozza M, Cristofoletti C, Bresin A, et al. Genetically driven CD39 expression affects Sézary cell viability, IL-2 production and detects two patient subsets with distinct prognosis. J Invest Dermatol. 2022;142(11):3009-3019.Google ScholarCrossrefSearch ADS 11.Rissiek A, Baumann I, Cuapio A, et al. The expression of CD39 on regulatory T cells is genetically driven and further upregulated at sites of inflammation. J Autoimmun. 2015;58:12-20.Google ScholarCrossrefSearch ADS 12.Schneider E, Winzer R, Rissiek A, et al. CD73-mediated adenosine production by CD8 T cell-derived extracellular vesicles constitutes an intrinsic mechanism of immune suppression. Nat Commun. 2021;12(1):5911.Google ScholarCrossrefSearch ADS PubMed 13.Quaglino P, Novelli M, Fava P, et al. CD38 expression by circulating and skin-infiltrating lymphocytes from Sézary syndrome patients: a flow cytometry and immunohistochemistry study. Dis Markers. 2022;2022:3424413.Google ScholarCrossrefSearch ADS PubMed 14.Fortunato O, Belisario DC, Compagno M, et al. CXCR4 inhibition counteracts immunosuppressive properties of metastatic NSCLC stem cells. Front Immunol. 2020;11:2168.Google ScholarCrossrefSearch ADS 15.de Andrade Mello P, Coutinho-Silva R, Savio LEB. Multifaceted effects of extracellular adenosine triphosphate and adenosine in the tumor-host interaction and therapeutic perspectives. Front Immunol. 2017;8:1526.Google ScholarCrossrefSearch ADS PubMed 16.Giuliani AL, Sarti AC, Di Virgilio F. Ectonucleotidases in acute and chronic inflammation. Front Pharmacol. 2020;11:619458.Google ScholarCrossrefSearch ADS PubMed 17.Yip L, Woehrle T, Corriden R, et al. Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J. 2009;23(6):1685-1693.Google ScholarCrossrefSearch ADS PubMed 18.Cristofoletti C, Bresin A, Picozza M, et al. Blood and skin-derived Sézary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance. Leukemia. 2019;33(5):1231-1242.Google ScholarCrossrefSearch ADS PubMed 19.Antonioli L, Fornai M, Blandizzi C, Pacher P, Hasko G. Adenosine signaling and the immune system: when a lot could be too much. Immunol Lett. 2019;205:9-15.Google ScholarCrossrefSearch ADS PubMed 20.Festag J, Thelemann T, Schell M, et al. Preventing ATP degradation by ASO-mediated knockdown of CD39 and CD73 results in A2aR-independent rescue of T cell proliferation. Mol Ther Nucleic Acids. 2020;21:656-669.Google ScholarCrossrefSearch ADS PubMed 21.Schiedel AC, Lacher SK, Linnemann C, Knolle PA, Muller CE. Antiproliferative effects of selective adenosine receptor agonists and antagonists on human lymphocytes: evidence for receptor-independent mechanisms. Purinergic Signal. 2013;9(3):351-365.Google ScholarCrossrefSearch ADS PubMed 22.Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol. 2001;54(3):249-264.Google ScholarCrossrefSearch ADS PubMed 23.Yegutkin GG. Adenosine metabolism in the vascular system. Biochem Pharmacol. 2021;187:114373.Google ScholarCrossrefSearch ADS PubMed 24.Najidh S, Tensen CP, van der Sluijs-Gelling AJ, et al. Improved Sézary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sézary syndrome. Blood. 2021;138(24):2539-2554.Google ScholarCrossrefSearch ADS PubMed © 2023 by The American Society of Hematology2023 © 2023 by The American Society of Hematology2023 You do not currently have access to this content. Sign in via your Institution